Nadim Russel
Research Abstract:
While the anti-HIV drugs effectively suppress viral replication in plasma and the peripheral tissues, the drugs are not able to penetrate to the CNS which is a critical viral reservoir. Since antiretroviral therapy has increased the life expectancy of infected individuals, it is likely that the prevalence of HIV-associated neurological disorders will continue to rise. Synthesis of a drug delivery system using Schiff base linker is proposed in this research. The Schiff base-conjugated β-CD drug delivery system will be synthesized using standard procedure in the literature. The thiolated ANG peptide (TFFYGGSRGKRNNFKTEEYC), a brain targeting ligand, will be attached to the Schiff base containing b-CD. Raltegravir, an inhibitor of HIV integrase enzyme, will be formulated into this drug delivery system. We anticipate that the cyclodextrin-based inclusion complexes will contribute to increasing the solubility, stability, and bioavailability of the anti-HIV drug, thus alleviating the mortality and morbidity associated with HIV infections. Furthermore, the ANG peptide-mediated delivery of antiviral drug to the CNS will contribute to reducing viral reservoirs in the CNS and neurological disorders associated with HIV infections. A significant progress has been made in the synthesis of this drug carrier molecule, which will be presented. Our future aims include the generation of nanoparticle delivery systems by changing the size and shape of the molecule.
Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.Insert text here.